Effect of different concentrations of sufentanil combined with ropivacaine on epidural fever during labor: A single-center retrospective study

Medicine (Baltimore). 2024 May 31;103(22):e38363. doi: 10.1097/MD.0000000000038363.

Abstract

Labor epidural analgesia (LEA) is associated with increased maternal body temperature; however, the responsible mechanism is unknown. Recent studies suggest that changes in EA affect the incidence of fever and that epidural sufentanil supplementation enhances analgesia and reduces the amount of local anesthetic. The aim of this study was to evaluate the effect of different concentrations of sufentanil combined with ropivacaine on intrapartum fever during delivery. We performed a retrospective study comparing maternal fever rates in patients receiving labor analgesia between December 2018 and January 2019. Each patient receiving different concentrations of sufentanil in their EA received either proposal H (0.08% ropivacaine + 0.4 µg/mL sufentanil) or proposal L (0.08% ropivacaine + 0.2 µg/mL sufentanil), with the same nulliparous status. The primary outcome of this study was the incidence of intrapartum maternal fever, which was defined as any temperature ≥ 38°C during labor using Fisher exact test. Secondary outcome measures included visual analog scale (VAS) pain scores, birth events, and neonatal outcomes. We observed a perinatal fever incidence rate of 11.7% in the group receiving proposal L, while the incidence rate was 19.8% in the group receiving proposal H (P = .001). Five hours after administration, the average body temperature of the puerpera decreased significantly in the proposal L group compared with proposal H group. In addition, treatment with 0.2 µg/mL sufentanil provided satisfactory pain relief during labor, shortened the first stage of labor and total labor time, reduced oxytocin use, and had no significant adverse effects on neonatal outcomes. EA may increase the risk of intrapartum epidural-associated fever. Compared with the 0.4 µg/mL sufentanil group, the 0.2 µg/mL sufentanil group can provide better analgesia and improve maternal fever. These retrospective results highlighted the importance of prospective and mechanistic studies of maternal fever associated with intraspinal analgesia.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Analgesia, Epidural* / adverse effects
  • Analgesia, Epidural* / methods
  • Analgesia, Obstetrical / adverse effects
  • Analgesia, Obstetrical / methods
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / adverse effects
  • Anesthetics, Local* / administration & dosage
  • Anesthetics, Local* / therapeutic use
  • Female
  • Fever* / epidemiology
  • Fever* / prevention & control
  • Humans
  • Incidence
  • Labor, Obstetric / drug effects
  • Pain Measurement
  • Pregnancy
  • Retrospective Studies
  • Ropivacaine* / administration & dosage
  • Ropivacaine* / therapeutic use
  • Sufentanil* / administration & dosage
  • Sufentanil* / adverse effects
  • Sufentanil* / therapeutic use

Substances

  • Sufentanil
  • Ropivacaine
  • Anesthetics, Local
  • Analgesics, Opioid